MetaVia, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on the stock and has a $20.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andrew Fein has given his Buy rating due to a combination of factors centered on DA-1726’s advancing clinical profile and MetaVia’s execution. He highlights that recent IRB clearance for Phase 1 Part 3 enables testing of higher DA-1726 doses over 16 weeks, which should more rigorously assess sustained efficacy and tolerability at 48 mg and 64 mg and move the program beyond early dose-finding into a more decision-critical phase.
Fein also notes that earlier 8-week data at 48 mg, achieved without titration, already showed notable weight loss, metabolic and liver benefits with a comparatively mild gastrointestinal burden versus approved GLP-1 agents. Coupled with a strengthened balance sheet that, in his view, funds operations through the next major data readout, and a clear differentiation strategy in both obesity and MASH, these elements underpin his conviction that DA-1726 remains the primary value driver and justify maintaining a Buy on MTVA despite a reduced $20 target price.